Immune related colitis - Immune Checkpoint Inhibitor Therapy- Toxicity Management

Publication: 02/06/2021  --
Last review: 01/01/1900  
Next review: 02/06/2024  
Clinical Guideline
CURRENT 
ID: 7027 
Approved By: Trust Clinical Guidelines Group 
Copyright© Leeds Teaching Hospitals NHS Trust 2021  

 

This Clinical Guideline is intended for use by healthcare professionals within Leeds unless otherwise stated.
For healthcare professionals in other trusts, please ensure that you consult relevant local and national guidance.

Immune Checkpoint Inhibitor Therapy- Toxicity Management

Immune related colitis

Summary of Guideline

Patients with immune related colitis with usually present with new onset of diarrhoea following commensal of the immune checkpoint inhibitor, this can either be through a gradual change in bowel habit or a sudden change. It is rare for a patient to present with an acute complication of immune related colitis e.g. bowel perforation. Patients presenting with new diarrhoea on ICPI therapies should have a full GI history taken to ensure any other risk factors for a new change in bowel habit are screened for (e.g. thyroid dysfunction, infective, diverticular disease) and also screen for symptoms of other immune related toxicities as it is possible to present with multiple toxicities at the same time.
Examination should assess for signs of dehydration and evidence of acute severe colitis (e.g. peritonism, abdominal distension).
Diagnosis is based on the exclusion of any other cause of diarrhoea in a patient receiving treatment with an ICPI, treatment should not be delayed whilst awaiting the results of any investigations.
Investigations are performed to look for any other cause for the change in bowel habit (e.g. infection) and are detailed further below. It is important that those with grade 3 and 4 colitis undergo an urgent flexible sigmoidoscopy to review the macroscopic and microscopic appearance of the bowel and all patients having sigmoidoscopy should have biopsies, even if the macroscopic appearance is normal.
Treatment is focused at suppressing the immune activation responsible for the inflammatory process and in the first instance this should be done with corticosteroids (administered orally or intravenously as per the severity based on grading the diarrhoea (see below) this will also dictate the regularity of monitoring. If steroids are not effective then patients may require further management with other immunosuppressive agents. Please see below for more details.

Back to top

Background

Immunotherapy is now an established therapeutic option across a growing number of malignancies. Some of the most commonly used agents include ipilimumab (anti-CTLA4), nivolumab (anti- PD1) and pembrolizumb (Anti-PD-L1).

These treatments however can lead to autoimmune-like adverse events related to their ability to induce the immune system. While the toxicities may be severe, early management can be associated with limited impact on organ function and quality of life.

Epidemiology
Gastrointestinal (GI) toxicity is one of the most commonly recognised adverse events. Diarrhoea is seen in 19% of patients receiving anti-PD-1/PD-L1, 33% receiving anti-CTLA-4 medications and 44% of patients receiving combination therapy.1,2 Colitis defined clinically, radiologically or endoscopically in patients receiving antiCTLA4 therapy has ranged from 8% to 22%.1

Back to top

Diagnosis

Clinical Evaluation
The pattern for developing colitis is unpredictable and can occur anytime during therapy. Figure 1 shows timing of developing GI symptoms on ipilimumab. Patients usually present with diarrhoea, abdominal pain, nausea, vomiting, haematochezia, weight loss and fever. In severe cases patient may become clinically dehydrated. Patients need to be graded from 1-4 according to clinical symptoms to aid investigation and management.

Figure 1. Timeline of ipilimumab related adverse event. Reprinted from (3) VC 2012 American Society of Clinical Oncology.

Back to top

 Investigation

 

  1. Infective causes of diarrhoea need to be ruled out by performing stool samples for microscopy and culture, ova, parasites, cryptosporidia and Clostridium difficile toxin.
  2. The sensitivity and specificity of faecal calprotectin are not yet known with conflicting evidence from observational studies.
  3. Baseline blood tests including FBC, U+E, LFT, TFTs and CRP should be obtained.
  4. The other possible differential is tumor related metastatic causes which would need to be ruled out in certain malignancies such as melanoma.
  5. Radiology: An abdominal plain film should be performed if patients complain of abdominal pain. In case of severe symptoms abdominal CT is required to rule out serious complications such as perforation.
  6. Endoscopic investigations: Flexible sigmoidoscopy with biopsies is the diagnostic standard for patients with grade 3-4 symptoms or those with persistent grade 2 symptoms. Opportunistic infections such as CMV infection need to be ruled out by immunohistochemical staining of biopsy samples. The inflammatory changes tend to be more diffuse rather than patchy. It should be noted that there are also emerging cases of microscopic colitis (particularly with pembolizumab or nivolumab), so histopathology results are still important if the colonic mucosa looks normal.4 Ileocolonoscopy should be considered in patients with treatment-refractory or persistent diarrhoea, particularly if the flexible sigmoidoscopy and biopsies are normal. Endoscopy and duodenal biopsies may also be important if colonoscopy and biopsies are normal.5(Please see the appendix below regarding the procedure for referral to endoscopy).
  7. In patients whom infliximab is being considered, screening for this should take place including, hepatitis B and C screens, HIV, Varicella zoster, quantiferon testing.

Back to top

Treatment/Management

Treatment of immunotherapy induced diarrhoea/colitis is based on the grading of symptoms (Figure 2). Patients with grade 1 symptoms should be managed with supportive measures such as loperamide, encouragement of oral fluids and electrolyte replacement (e.g. dioralyte) solution. Those with persistent and/or worsening grade 1 symptoms or those with grade 2 toxicity should commence prednisolone. The starting dose of prednisolone is 60 mg OD and this is tapered by 10 mg every 5 days. Patients should also receive bone protection and PPI cover during steroid treatment alongside PJP prophylaxis using co-trimoxazole (please see separate steroid guideline for further details).

Patients with persistent, worsening or relapsing grade 2 symptoms or those with severe grade 3/4 toxicity should be admitted for IV methylprednisolone at a dose of 2 mg/kg/day. On admission patients need to be screened for infliximab suitability by performing Hepatitis B+C screen, VZV IgG and a recent CXR to rule out latent TB. Patients need to be monitored closely for 72 hours. Patients who respond to IV steroids should switch to oral tapering form after 3-5 days. Patients who do not respond to IV steroids or those who have a relapse requiring an increase in the dose of steroids should be switched to infliximab, providing there are no contra-indications. Infliximab is given at a dose of 5 mg/kg. A further dose 2 weeks later may be required in some patients. Rarely a third dose 6 weeks later may be needed. Overall one third to two thirds of patients fail to respond to steroids.

Figure 2. Management of immune colitis based on grade

In patients whom there is a clinical concern regarding escalation of treatment then specialist gastroenterology advice can be sought via the on-call consultant via ward J91 or J92 or the on call consultant on the weekend. For patients who are not responding to infliximab there is the potential to escalate treatment further but this would require individual patient discussion and funding discussion.

 

Provenance

Record: 7027
Objective:

Immune checkpoint inhibitor therapies (ICPIs: anti-CTLA4, anti-PD-1, anti-PD-L1 therapies) have been in routine use in the management of cancers for almost a decade. It is well recognised that patients receiving this class of systemic anti-cancer therapies are at risk of multiple and wide ranging toxicities from these treatments owing to immune activation against self-antigens outside of the therapeutic indication of the drug(s).Immune-related colitis is well documented in the case of these patients and this document aims to provide the clinician with an initial plan for investigation and management of patients who present with new colitis symptoms whilst undergoing treatment with these drugs.

Clinical condition:

Immune-related colitis (in patients undergoing therapy with immune checkpoint inhibitors). pembrolizumab, nivolumab, atezolizumab, avelumab, ipilimumab, durvalumab.

Target patient group: Those patients who are receiving or have previously received treatment with immune checkpoint inhibitor therapies.
Target professional group(s): Pharmacists
Pharmacists
Primary Care Doctors
Primary Care Doctors
Secondary Care Doctors
Secondary Care Doctors
Adapted from:

Evidence base

  1. Haanen J, Carbonnel F, Robert C, et al. Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2017; 28 (suppl 4): iv119–iv142.
  2. Gupta A, De Felice KM, Loftus EV et al. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015; 42: 406–417.
  3. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691–2697.
  4. Choi K, Abu-Sbeih, H, Samdani R, et al. Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? IBD 2019; 25(2): 385-393
  5. Powell N, Ibraheim H, Raine T et al. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol 2020; 5:680-98

Approved By

Trust Clinical Guidelines Group

Document history

LHP version 1.0

Related information

Not supplied

Equity and Diversity

The Leeds Teaching Hospitals NHS Trust is committed to ensuring that the way that we provide services and the way we recruit and treat staff reflects individual needs, promotes equality and does not discriminate unfairly against any particular individual or group.